ATXS
Price
$5.65
Change
-$0.11 (-1.91%)
Updated
Jun 25 closing price
Capitalization
318.85M
46 days until earnings call
ERAS
Price
$1.38
Change
-$0.07 (-4.83%)
Updated
Jun 25 closing price
Capitalization
390.94M
42 days until earnings call
Interact to see
Advertisement

ATXS vs ERAS

Header iconATXS vs ERAS Comparison
Open Charts ATXS vs ERASBanner chart's image
Astria Therapeutics
Price$5.65
Change-$0.11 (-1.91%)
Volume$199.71K
Capitalization318.85M
Erasca
Price$1.38
Change-$0.07 (-4.83%)
Volume$879.99K
Capitalization390.94M
ATXS vs ERAS Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. ERAS commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (ATXS: $5.65 vs. ERAS: $1.38)
Brand notoriety: ATXS and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 36% vs. ERAS: 62%
Market capitalization -- ATXS: $318.85M vs. ERAS: $390.94M
ATXS [@Biotechnology] is valued at $318.85M. ERAS’s [@Biotechnology] market capitalization is $390.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 6 bearish.
  • ERAS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -4.07% price change this week, while ERAS (@Biotechnology) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +31.79%, and the average quarterly price growth was +15.79%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($391M) has a higher market cap than ATXS($319M). ATXS YTD gains are higher at: -36.801 vs. ERAS (-45.020). ATXS has higher annual earnings (EBITDA): -124.4M vs. ERAS (-150.24M). ERAS (305M) and ATXS (295M) have equal amount of cash in the bank . ATXS has less debt than ERAS: ATXS (5.06M) vs ERAS (50.8M). ATXS (0) and ERAS (0) have equivalent revenues.
ATXSERASATXS / ERAS
Capitalization319M391M82%
EBITDA-124.4M-150.24M83%
Gain YTD-36.801-45.02082%
P/E RatioN/AN/A-
Revenue00-
Total Cash295M305M97%
Total Debt5.06M50.8M10%
FUNDAMENTALS RATINGS
ATXS: Fundamental Ratings
ATXS
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATXSERAS
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
79%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYAWX108.96N/A
N/A
Rydex S&P 500 Pure Growth H
SEPKX57.86N/A
N/A
Allspring Mid Cap Growth Fund - Cl Admin
MTRRX19.58N/A
N/A
MFS Total Return R2
TWMIX12.47N/A
N/A
American Century Emerging Markets Inv
LGCAX18.52N/A
N/A
Lord Abbett Global Equity A

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-4.83%
RVMD - ERAS
57%
Loosely correlated
-4.05%
LRMR - ERAS
54%
Loosely correlated
+8.70%
XNCR - ERAS
53%
Loosely correlated
+3.51%
ATXS - ERAS
52%
Loosely correlated
-1.91%
APGE - ERAS
52%
Loosely correlated
-1.29%
More